Tanaka Toru, Sasaki Naoto, Rikitake Yoshiyuki
Laboratory of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe 658-8558, Japan.
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 658-8558, Japan.
J Clin Med. 2021 Dec 16;10(24):5907. doi: 10.3390/jcm10245907.
Atherosclerotic diseases, including ischemic heart disease and stroke, are a main cause of mortality worldwide. Chronic vascular inflammation via immune dysregulation is critically involved in the pathogenesis of atherosclerosis. Accumulating evidence suggests that regulatory T cells (Tregs), responsible for maintaining immunological tolerance and suppressing excessive immune responses, play an important role in preventing the development and progression of atherosclerosis through the regulation of pathogenic immunoinflammatory responses. Several strategies to prevent and treat atherosclerosis through the promotion of regulatory immune responses have been developed, and could be clinically applied for the treatment of atherosclerotic cardiovascular disease. In this review, we summarize recent advances in our understanding of the protective role of Tregs in atherosclerosis and discuss attractive approaches to treat atherosclerotic disease by augmenting regulatory immune responses.
动脉粥样硬化性疾病，包括缺血性心脏病和中风，是全球范围内主要的死亡原因。通过免疫失调引起的慢性血管炎症在动脉粥样硬化的发病机制中起关键作用。越来越多的证据表明，负责维持免疫耐受和抑制过度免疫反应的调节性T细胞（Tregs），通过调节致病性免疫炎症反应，在预防动脉粥样硬化的发生和发展中发挥重要作用。已经开发出几种通过促进调节性免疫反应来预防和治疗动脉粥样硬化的策略，并且可以在临床上应用于治疗动脉粥样硬化性心血管疾病。在这篇综述中，我们总结了我们对Tregs在动脉粥样硬化中的保护作用的最新认识，并讨论了通过增强调节性免疫反应来治疗动脉粥样硬化疾病的有吸引力的方法。
